Telephone:
(925) 558-5040
en
At Crystal Pharmatech, we provide integrated formulation development services for oral drug products, helping innovative biotech and pharmaceutical companies accelerate molecules from First-in-Human (FIH) studies to commercial manufacturing.
Unlike traditional “fit-for-purpose” strategies that often create costly downstream reformulation risks, our First-Time-Right philosophy ensures robust bioavailability, scalable manufacturing, and regulatory readiness from day one.
Early shortcuts — such as powder-in-capsule or super placebo approaches — may slightly speed initial studies but frequently result in:
Reformulation after POC
Bioavailability variability
Additional human PK bridging studies with high cost
Regulatory delays
Our approach eliminates these risks through integrated design, predictive modeling, and scalable process with line of sight for late stage development.
A well-designed formulation must balance desired bioavailability, stability (physicochemical, and microbiological), and a scalable manufacturing process. We follow the M3 drug product development philosophy, creating tailor-made formulation designs for each molecule.
We begin with a deep scientific understanding of your compound:
Target Product Profile (TPP) alignment
Early DMPK and pharmacodynamics assessment
Safety margin integration
Biopharmaceutics Classification System (BCS) positioning
We analyze the physical and chemical foundation of the formulation:
Crystal form and solid-state properties
Crystallinity and polymorphism
Excipient compatibility and functionality
Mechanical and compaction behavior
Release and stability characteristics
We design for the final patient experience and industrial scale drug product:
Label-driven formulation development strategy
CQA/CPP impact analysis
Risk-based QbD strategy
Regulatory-compliant scalability
Crystal Pharmatech boasts a leadership team with deep expertise and state-of-the-art pilot plants. We strive to be your trusted partner, providing the technical and analytical data required for successful IND filings and beyond.
● Speed to FIH: Achieving "First-Time-Right with Line-of-Sight".
● Solubility Enhancement: Utilizing enabling technologies to improve bioavailability.
● Analytical Excellence: Developing and implementing validated analytical processes.
● Cost & Time Optimization: Streamlining the path forward with expert formulation recommendations.
● Scientific Expertise: A leadership team with an average of over 25 years of experience in multinational pharmaceutical companies.
● Proven Track Record: Successfully supported the development of over 100 innovative drugs, with 15 successfully commercialized.
● Top-of-the-Line Facilities: State-of-the-art pilot plants and labs equipped for R&D, advanced analysis, and manufacturing.
● Global Quality Standards: cGMP systems meeting NMPA, FDA, and EMA requirements, with 31 successful audits from global clients as of January 2026.
Subscribe to be the first to get the updates!